U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967181) titled 'A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults' on May 01.
Brief Summary: The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Mumps
Intervention:
BIOLOGICAL: CVM150
CVM150- Live PIV5-based MuV vaccine expressing the MuV (Iowa strain/2006) F and HN proteins formulated in 1x sucrose phosphate glutamate ([SPG]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
BIOLOGICAL: CVM26
CVM26: A live, attenuated MuV vaccine based on Iowa strain genetically...